

WAYFIND-R: Delivering a high-quality real-world data (RWD) global registry of patients diagnosed with a solid tumor and profiled with next-generation sequencing (NGS)

Christophe Le Tourneau,¹ Allan Hackshaw,² Jean-Yves Blay,³ Jan Geissler,⁴ Clare Turnbull,⁵ Camille Perret,⁶ Olga Skatkova,⁶ Martina von Meyenn,⁶ Rodrigo Dienstmann⁷

¹Institut Curie, Paris, France; ²UCL Cancer Institute, London, UK; ³Centre Léon Bérard, Lyon, France; ⁴Patvocates, Munich, Germany; ⁵The Institute of Cancer Research, London, UK; ⁶F. Hoffmann-La Roche Ltd, Basel, Switzerland; ⁷Oncoclínicas Precision Medicine, Oncoclínicas Grupo, São Paulo, Brazil

Summary

WAYFIND-R will inform on best practice for NGS-based treatment decisions by clinicians, foster global collaborations between cancer centers (enabling robust conclusions to be drawn regarding outcome data), aid understanding of disparities in patients' access to advanced diagnostics and therapies, and ultimately drive advances in precision oncology

Poster




<https://bit.ly/3voA3jU>

Supplement




<https://bit.ly/3laGUjE>


Copies of this poster obtained through quick response and/or text key codes are for personal use only and may not be reproduced without written permission of the authors.




WAYFIND-R (NCT04529122), a global, prospective, longitudinal, generalizable registry, with NGS and standardized data collection to enhance data quality and limit data missingness



Eligibility criteria



Computerized systems at three levels and **Medical information collected at baseline and at least every 6 months across the entire patient journey (Supplement)**



*Access granted by an independent data access committee. To optimize data sharing while meeting General Data Protection Regulation and local data privacy requirements, the platform will use advanced technology to enable data privacy by design. †As of February 14, 2022, 73 patients have been enrolled.

Abbreviations: MTB, molecular tumor board; NGS, next-generation sequencing; RWD, real-world data. **References:** 1. Malone ER, et al. *Genome Med* 2020; 12:8; 2. Lewis JRR, et al. *JCO Precis Oncol* 2017; 1:1-11. **Acknowledgments** Research support for third-party writing/printing assistance for this poster, furnished by Stephen Salem, BSc, of Health Interactions, was provided by F. Hoffmann-La Roche Ltd. **Conflicts of interest** CLT has received grants/contracts from MSD, has received travel expenses from MSD, BMS, and AstraZeneca, has received honoraria from and performed a consulting/advisory role for BMS, MSD, Merck Serono, Roche, Nanobiotix, GSK, Rakuten, Seattle Genetics, and AstraZeneca, and has been paid by Roche as an external consultant. Please refer to the Supplement for all author conflicts of interest. This analysis was sponsored by F. Hoffmann-La Roche Ltd.